Brain Vitale
Brain Vitale, licence 80084784: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Genius Bypass
- Licence holder
- Designs for Health
- NPN or DIN-HM
- 80084784
- Status
- Active licence
- Licence date
- 3 May 2018
- Revision date
- 9 January 2023
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sel interne de (2R)-2-(Acétyloxy)-3-carboxy-N,N,N-triméthyl-1-propanaminium Source : N-acétyl L-chlorhydrate de carnitine | 250.0 mg | Not calculated |
| Cytidine-5'-pyrophosphate de choline(ester) Source : Citicoline | 125.0 mg | Not calculated |
| L-alpha-Glycérophosphorylcholine Source : Alfoscérate de choline | 100.0 mg | Not calculated |
| Phosphatidylsérine Source : Lécithine de soja enrichie en phosphatidylsérine | 50.0 mg | Not calculated |
| Ginkgo biloba Source : Feuille Extract : Matériel brut sec Extraction ratio : 55:1 Dry plant equivalent : 2750 mg Potency : 6.0 % Terpene lactones | 50.0 mg | Not calculated |
| Coffea arabica Source : Fruit Extract : Matériel brut sec Extraction ratio : 20:1 Dry plant equivalent : 1000 mg | 50.0 mg | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 24.0 % Flavonoid glycosides | Not specified | Not calculated |
Non-medicinal ingredients
Phosphate dicalcique, Stéarate de magnésium, Dioxyde de silicium, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 2.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Helps to enhance cognitive function in adults. Helps to enhance memory in adults. Helps to support peripheral circulation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80084784
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Has the product changed? Photograph the packaging.